ClinicalTrials.gg
CompletedNCT02842827Updated Jul 11, 2023Results posted

A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)

A Phase 1/2 interventional study of bomedemstat and tretinoin in Acute Myeloid Leukemia and Myelodysplastic Syndrome, sponsored by Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA). Completed at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-11.

Sponsored by Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Leukemia, Myeloid, Acute by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Leukemia, Myeloid, Acute · Merck & Co., Inc.

Enrollment
6th of 12
45 · median 37
Started
2016
the only one that year
Phase 1/2
2 of 12
none open now
Registered
9th of 12
by date

Among the 12 studies in Leukemia, Myeloid, Acute by Merck & Co., Inc, this one is the 6th largest by enrollment, is the only one that started in 2016, is one of 2 in phase 1/2, and was the 9th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

None of the 12 studies in Leukemia, Myeloid, Acute by Merck & Co., Inc is open now. The open studies under Leukemia, Myeloid, Acute, anywhere →

Where they have run

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Leukemia, Myeloid, Acute by Merck & Co., Inc as a file.
02

Study summary

This is an open label study of the dose and duration of an orally administered lysine-specific demethylase 1 (LSD1) inhibitor, bomedemstat, in patients with high-risk acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Some participants may also receive all-trans retinoic acid (ATRA; also known as tretinoin and Vesanoid®) in combination with bomedemstat. This study investigates the following:

  • The safety and tolerability of bomedemstat with and without ATRA
  • The pharmacodynamic effect of different doses of bomedemstat and treatment durations, as well as bomedemstat administered in combination with ATRA
  • The pharmacokinetics of bomedemstat with and without ATRA
03

Conditions studied

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome

Keywords

  • LSD1
  • High-risk Acute Myeloid Leukemia
  • High-risk Myelodysplastic Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

The main inclusion and exclusion criteria include but are not limited to the following:

Inclusion criteria

Inclusion Criteria:

High-risk Acute Myeloid Leukemia (AML)

  • Have a diagnosis of AML according to the World Health Organization (WHO) criteria
  • Have an (ECOG) performance status score ≤2
  • Have AML that is classified as high risk as defined by one of the following: ≥ 60 years of age who were not candidates for or have refused standard chemotherapy; ≥18 years of age with de novo or secondary AML who were not expected to benefit from standard remission-induction chemotherapy; or had AML after no more than 3 .

High-risk Myelodysplastic Syndromes (MDS)

  • Have a diagnosis of myelodysplastic syndromes according to the World Health Organization (WHO) criteria
  • Have either an International Prognostic Scoring System (IPSS) score equivalent to intermediate-2 risk or higher, or a Revised International Prognostic Scoring System (IPSS-R) score equivalent to intermediate risk or higher.
  • Have MDS that is classified as high risk as defined by one of the following: participants who have failed first-line therapy; or treatment-related MDS, except if it is associated with favorable cytogenetics, and not a candidate for stem cell transplantation
  • Prior stem cell transplant is allowed if a minimum of 3 months has elapsed from the time of transplant and the patient has recovered from transplant-associated toxicities
  • Prior allogeneic stem cell transplant is allowed, provided all of the following criteria are met: transplant was >120 days prior to study enrollment; no medications have been taken for at least 1 month; and no active (GVHD), excluding Grade 1 skin GVHD
  • Has a >12 weeks

Exclusion criteria

Exclusion Criteria:

  • Is receiving other treatments for the condition (with exceptions and time limits)
  • Has had major surgery in last 4 weeks or minor surgery in the last 2 weeks
  • Has a scheduled hematopoietic stem-cell transplant
  • Is currently using prohibited medications
  • Has clinical evidence of central nervous system (CNS) or pulmonary leukostasis, disseminated intravascular coagulation, or CNS leukemia
  • Has a concurrent second active and non-stable
  • Has an uncontrolled active infection
  • Has known (HIV) infection or active or virus infection
  • Has used an agent within last 14 days
  • Is a pregnant or lactating females
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Cohort 1a: bomedemstat 0.75 mg/kg/day

    Participants receive bomedemstat 0.75 mg/kg/day orally in 14-day cycles consisting of 7 days of treatment and 7 days of rest. Participants will receive up to 4 cycles (14-day cycles) for up to a total of up 56 days (28 days on treatment).

    Drug: bomedemstat

  • Experimental
    Cohort 1b: bomedemstat 1.5 mg/kg/day

    Participants receive bomedemstat 1.5 mg/kg/day orally in 14-day cycles consisting of 7 days of treatment and 7 days of rest. Participants will receive up to 4 cycles (14-day cycles) for up to a total of up 56 days (28 days on treatment).

    Drug: bomedemstat

  • Experimental
    Cohort 1c: bomedemstat 3 mg/kg/day

    Participants receive bomedemstat 3 mg/kg/day orally in 14-day cycles consisting of 7 days of treatment and 7 days of rest. Participants will receive up to 4 cycles (14-day cycles) for up to a total of up 56 days (28 days on treatment).

    Drug: bomedemstat

  • Experimental
    Cohort 1d: bomedemstat 6 mg/kg/day orally

    Participants receive bomedemstat 6 mg/kg/day orally in 14-day cycles consisting of 7 days of treatment and 7 days of rest. Participants will receive up to 4 cycles (14-day cycles) for up to a total of up 56 days (28 days on treatment).

    Drug: bomedemstat

  • Experimental
    Cohort 1x3: bomedemstat 3 mg/kg/day orally plus tretinoin 45 mg/m^2 /day3

    Participants receive bomedemstat 3 mg/kg/day orally plus tretinoin 45 mg/m\^2/day orally in 14-day cycles consisting of 7 days of treatment and 7 days of rest. Participants will receive up to 4 cycles (14-day cycles) for up to a total of up 56 days (28 days on treatment).

    Drug: bomedemstat · Drug: tretinoin

  • Experimental
    Cohort 1x6: bomedemstat 6 mg/kg/day plus tretinoin 45 mg/m^2/day

    Participants receive bomedemstat 6 mg/kg/day orally plus tretinoin 45 mg/m\^2/day orally in 14-day cycles consisting of 7 days of treatment and 7 days of rest. Participants will receive up to 4 cycles (14-day cycles) for up to a total of up 56 days (28 days on treatment).

    Drug: bomedemstat · Drug: tretinoin

  • Experimental
    Cohort 3x: bomedemstat 6 mg/kg/day plus tretinoin 45 mg/m^2/day

    Participants receive bomedemstat 6 mg/kg/day orally plus tretinoin 45 mg/m\^2/day orally in 21-day cycles consisting of 14 days of treatment and 7 days of rest. Participants will receive up to 2 cycles (21-day cycles) for up to a total of up 42 days (28 days on treatment).

    Drug: bomedemstat · Drug: tretinoin

  • Experimental
    Cohort 4x: bomedemstat 6 mg/kg/day plus tretinoin 45 mg/m^2/day

    Participants receive bomedemstat 6 mg/kg/day orally for 21 days plus tretinoin 45 mg/m\^2/day orally in 28-day cycles consisting of 21 days of treatment and 7 days of rest. Participants will receive at least 1 cycle (28-day cycles) and will receive subsequent cycles at the discretion of the investigator.

    Drug: bomedemstat · Drug: tretinoin

Interventions

  • oral administration

    Also known as: MK-3543, IMG-7289

  • oral administration

    Also known as: ATRA®, Vesanoid®, all-trans retinoic acid,

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced an Adverse Event (AE)

    An AE was defined as any undesirable physical, psychological, or behavioral effect experienced by a participant during participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not related to the study drug. This included any untoward signs or symptoms experienced by the participant from the time of first dose until completion of the study. The number of participants who experienced an AE is presented.

    Time frame: Up to approximately 24 months

  2. Number of Participants Who Experienced a Serious Adverse Event (SAE)

    An SAE was defined as any adverse event, whether or not related to the study drug, that resulted in any of the following outcomes: * Death * Life-threatening experience * Required or prolonged inpatient hospitalization * Persistent or significant disability/incapacity * Congenital anomaly * Important medical events that, based upon appropriate medical judgment, may have jeopardized the participant and may have required medical or surgical intervention to prevent one of the outcomes listed above. The number of participants who experienced an SAE is presented.

    Time frame: Up to approximately 24 months

  3. Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)

    An AE was defined as any undesirable physical, psychological, or behavioral effect experienced by a participant during participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not related to the study drug. This included any untoward signs or symptoms experienced by the participant from the time of first dose until completion of the study. The number of participants who discontinued study treatment due to an AE is presented.

    Time frame: Up to approximately 18 months

  4. Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT)

    DLTs were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. A DLT was defined as any of the following events that occurs during the DLT evaluation period and is considered by the Investigator possibly, probably, or definitely related to bomedemstat: * A clinically significant bleeding event * Any Grade 4 or 5 non-haematologic adverse event * Any Grade 3 non-haematologic adverse event with failure to recover to Grade 1 within 7 days of drug cessation, with the following exceptions: ≥ Grade 3 nausea, vomiting or diarrhoea that responds to standard medical care and ≥ Grade 3 aesthenia lasting less than 14 days * Any Grade 3 electrolyte abnormality unrelated to the underlying malignancy and persisting greater than 24 hours. Per protocol, DLTs were measured during the first 28-day treatment period. The number of participants who experienced a DLT is presented.

    Time frame: Up to approximately 28 Days

  5. Number of Participants Experiencing Any Grade 3 to 5 Adverse Events (AE) as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03

    AEs were graded for severity on a scale of 1 to 5 using CTCAE criteria. Grade 1=mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2=moderate, minimal, local, or noninvasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3=severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care. Grade 4=life-threatening consequences with urgent intervention indicated. Grade 5 =death related to AE. The number of participants who experienced any Grade 3 to 5 AE is reported.

    Time frame: Up to approximately 24 months

  6. Number of Participants Who Experienced a Medical Event of Interest (MEOI)

    Medical Events of Interest (MEOI) were adverse events that did not meet any criteria for a serious adverse event but were of particular interest in the context of the study. MEOIs included bleeding due to low platelets; electrocardiogram (ECG) QT corrected interval prolonged 481-500 milliseconds; and infection where, at a minimum, oral antibiotic, antifungal, or antiviral intervention is indicated. The number of participants with MEOIs is presented.

    Time frame: Up to approximately 24 months

  7. Maximum Concentration (Cmax) of Bomedemstat Alone or Administered With Tretinoin

    Cmax was defined as the maximum concentration of bomedemstat observed after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the CMax of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). Unbound plasma concentrations of bomedemstat were estimated by assuming that protein binding was 60.57%. For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the Cmax was determined for participants in Cohort 1. The LOQ of the assay was 1 ng/mL. The Cmax of bomedemstat in unbound plasma is presented.

    Time frame: Cycle 1 Day 1: predose and 1, 2, 3, and 24 hours postdose; Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose

  8. Time to Maximum Concentration (Tmax) of Bomedemstat Alone or Administered With Tretinoin

    Tmax was the time required to reach the maximum concentration of bomedemstat observed after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the TMax of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the Tmax was determined for participants in Cohort 1. The Tmax of bomedemstat in plasma is presented.

    Time frame: Cycle 1 Day 1: predose and 1, 2, 3, and 24 hours postdose; Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose

  9. Area Under the Concentration Time Curve From Time 0 to 24 Hours (AUC0-24hr) Postdose of Bomedemstat Alone or Administered With Tretinoin

    AUC0-24hr was defined as the total exposure of bomedemstat over 24 hours after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the AUC 0-24hr of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). Unbound plasma concentrations of bomedemstat were estimated by assuming that protein binding was 60.57%. For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the AUC 0-24hr was determined for participants in Cohort 1. The AUC 0-24hr of bomedemstat in unbound plasma is presented.

    Time frame: Cycle 1 Day 1: predose and 1, 2, 3, and 24 hours postdose; Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose

  10. Elimination Half Life (t1/2) of Bomedemstat Alone or Administered With Tretinoin

    t1/2 was the time required to divide the bomedemstat concentration by two after reaching pseudo-equilibrium after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the t1/2 of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the t1/2 was determined for participants in Cohort 1. The t1/2 of bomedemstat in plasma is presented.

    Time frame: Cycle 1 Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose

  11. Apparent Total Body Clearance (CL/F) of Bomedemstat Alone or Administered With Tretinoin

    CL/F was the volume of plasma from which bomedemstat was eliminated per unit of time after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the CL/F of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the CL/F was determined for participants in Cohort 1. The CL/F of bomedemstat in plasma is presented.

    Time frame: Cycle 1 Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose

  12. Volume of Distribution (Vz/F) of Bomedemstat Alone or Administered With Tretinoin

    Vz/F was the volume of distribution of bomedemstat during the terminal phase after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the Vz/F of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the Vz/F was determined for participants in Cohort 1. The Vz/F of bomedemstat in plasma is presented.

    Time frame: Cycle 1 Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose

  13. Terminal Elimination Rate Constant (Kel) of Bomedemstat Alone or Administered With Tretinoin

    kel was the rate at which bomedemstat was removed from the body by excretion or metabolism after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the kel of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). kel was obtained from the slope of the line, fitted by linear least squares regression, through the terminal points of the log (base e) concentration-time profiles. For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the kel was determined for participants in Cohort 1. The kel of bomedemstat in plasma is presented.

    Time frame: Cycle 1 Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose

  14. Event-free Survival (EFS) For High-risk Acute Myeloid Leukemia (AML) Participants

    EFS was defined as the time from the first dose of study treatment to the date of a documented EFS event of resistance, relapse, progression, or death due to any cause as assessed by the investigator. Participants without documented events were censored at the date of the last disease assessment. The EFS, calculated using the Kaplan-Meier method, is presented.

    Time frame: Up to approximately 24 months

  15. Event-free Survival (EFS) For High-risk Myelodysplastic Syndromes (MDS) Participants

    EFS was defined as the time from the first dose of study treatment to the date of a documented EFS event of resistance, relapse, progression, or death due to any cause as assessed by the investigator. Participants without documented events were censored at the date of the last disease assessment. The EFS, calculated using the Kaplan-Meier method, is presented.

    Time frame: Up to approximately 24 months

  16. Overall Survival (OS) For High-risk Acute Myeloid Leukemia (AML) Participants

    OS was defined as the time from the first dose of study treatment until death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. The OS, calculated using the Kaplan-Meier method, is presented.

    Time frame: Up to approximately 24 months

  17. Overall Survival (OS) For High-risk Myelodysplastic Syndromes (MDS) Participants

    OS was defined as the time from the first dose of study treatment until death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. The OS, calculated using the Kaplan-Meier method, is presented.

    Time frame: Up to approximately 24 months

  18. Objective Response Rate (ORR) For High-risk Acute Myeloid Leukemia (AML) Participants Determined Using the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2003) and Assessed by the Investigator

    ORR was the percentage of participants with a response of complete remission (CR), CR with incomplete recovery (Cri), morphologic leukaemia-free state (MLFS), partial remission (PR), cytogenetic CR (CRc), molecular CR (CRm), or stable disease (SD): * CR: \<5% bone marrow (BM) blasts or blasts with Auer rods; no extramedullary disease (EMD); absolute neutrophil count ≥1000/μL; platelets ≥100,000/μL; independent of transfusion * Cri: CR with residual neutropenia (\<1,000/μL) or thrombocytopenia (\<100,000/μL); no EMD; does not require transfusion independence (TI) * MLFS: \<5% blasts in BM with marrow spicules; no EMD; does not require TI * PR: ≥ 50% decrease in BM blasts to a range of 5%-25%; Neutrophils ≥ 1,000/μL; Platelets ≥ 100,000/μL; independent of transfusion. ≤ 5% blasts is PR if Auer rods present * CRc: CR+reversion to a normal karyotype if initially abnormal * CRm: CR+no evidence of residual disease by molecular testing * SD: No evidence of CR, PR, progression, new dysplastic changes

    Time frame: Up to approximately 24 months

  19. Best Overall Response (BOR) For High-risk Acute Myeloid Leukemia (AML) Participants Determined Using the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2003) and Assessed by the Investigator

    BOR was the percentage of participants with a best overall response of CR, Cri, MLFS, PR, CRc, CRm, or SD: * CR: \<5% bone marrow (BM) blasts or blasts with Auer rods; no extramedullary disease (EMD); absolute neutrophil count ≥1000/μL; platelets ≥100,000/μL; independent of transfusion * Cri: CR with residual neutropenia (\<1,000/μL) or thrombocytopenia (\<100,000/μL); no EMD; does not require transfusion independence (TI) * MLFS: \<5% blasts in BM with marrow spicules; no EMD; does not require TI * PR: ≥ 50% decrease in BM blasts to a range of 5%-25%; Neutrophils ≥ 1,000/μL; Platelets ≥ 100,000/μL; independent of transfusion. ≤ 5% blasts is PR if Auer rods present * CRc: CR+reversion to a normal karyotype if initially abnormal * CRm: CR+no evidence of residual disease by molecular testing * SD: No evidence of CR, PR, progression, new dysplastic changes

    Time frame: Up to approximately 24 months

  20. Objective Response Rate (ORR) For High-risk Myelodysplastic Syndromes (MDS) Participants Determined Using the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2006) and Assessed by the Investigator

    ORR was the percentage of participants with a response of complete remission (CR), partial remission (PR), marrow CR (CRm), cytogenetic response (CyR), or stable disease (SD) lasting for ≥4 weeks: * CR: ≤5% myeloblasts in the bone marrow (BM) with normal maturation of all cell lines; persistent dysplasia will be noted; Hgb ≥11 g/dL, Platelets ≥100 X 10\^9/L, Neutrophils ≥1.0 X 10\^9/L, and 0% Blasts in the peripheral blood * PR: All CR criteria if abnormal before treatment except: BM blasts decreased by ≥50% over pretreatment but still \>5%. Cellularity and morphology not relevant * CRm: ≤ 5% myeloblasts in BM and decrease by ≥50% over pretreatment. Hematological improvement responses in the peripheral blood will be noted in addition to bone marrow CR. * CyR: Complete=Disappearance of the chromosomal abnormality without appearance of new ones. Partial= ≥50% reduction of the chromosomal abnormality * SD: Failure to achieve at least PR, but no evidence of progression for \>8 weeks

    Time frame: Up to approximately 24 months

  21. Best Overall Response (BOR) Assessed by the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2006): High-risk Myelodysplastic Syndromes (MDS) Participants

    BOR was the percentage of participants with a best overall response of CR, PR, CRm, CyR, or SD lasting for ≥4 weeks: * CR: ≤5% myeloblasts in the bone marrow (BM) with normal maturation of all cell lines; persistent dysplasia will be noted; Hgb ≥11 g/dL, Platelets ≥100 X 10\^9/L, Neutrophils ≥1.0 X 10\^9/L, and 0% Blasts in the peripheral blood * PR: All CR criteria if abnormal before treatment except: BM blasts decreased by ≥50% over pretreatment but still \>5%. Cellularity and morphology not relevant * CRm: ≤ 5% myeloblasts in BM and decrease by ≥50% over pretreatment. Hematological improvement responses in the peripheral blood will be noted in addition to bone marrow CR. * CyR: Complete=Disappearance of the chromosomal abnormality without appearance of new ones. Partial= ≥50% reduction of the chromosomal abnormality * SD: Failure to achieve at least PR, but no evidence of progression for \>8 weeks

    Time frame: Up to approximately 24 months

Secondary outcomes

  1. Maximum Percent Change From Baseline Up to 28 Days of Treatment in Erythrocyte Count in Whole Blood After Administration of Bomedemstat

    Whole blood samples were collected at time intervals during the first 4 cycles (Cycle length = 7 days of treatment and 7 days of rest for a total of 14 days), which corresponds to 28 days on treatment. The percent change from baseline in erythrocyte count was measured. Baseline was the erythrocyte count at screening or the last available observation prior to the first dose of study drug. An analysis of treatment effect between the doses was determined using a Kruskal-Wallis test. This analysis was done to support the evaluation of plasma concentrations (Cmax and Cmin) and exposure (AUC) on haematopoiesis. Per protocol, the analysis was pre-specified to be done on participants that received bomedemstat alone. The maximum percent change from baseline in erythrocyte count is presented.

    Time frame: Baseline (prior to first dose of study drug) and up to 28 days

  2. Maximum Percent Change From Baseline Up to 28 Days of Treatment in Neutrophil Count in Whole Blood After Administration of Bomedemstat

    Whole blood samples were collected at time intervals during the first 4 cycles (Cycle length = 7 days of treatment and 7 days of rest for a total of 14 days), which corresponds to 28 days on treatment. The percent change from baseline in neutrophil count was measured. Baseline was the neutrophil count at screening or the last available observation prior to the first dose of study drug. An analysis of treatment effect between the doses was determined using a Kruskal-Wallis test. This analysis was done to support the evaluation of plasma concentrations (Cmax and Cmin) and exposure (AUC) on haematopoiesis. Per protocol, the analysis was pre-specified to be done on participants that received bomedemstat alone. The maximum percent change from baseline in neutrophil count is presented.

    Time frame: Baseline (prior to first dose of study drug) and up to 28 days

  3. Maximum Percent Change From Baseline Up to 28 Days of Treatment in Platelet Count in Whole Blood After Administration of Bomedemstat

    Whole blood samples were collected at time intervals during the first 4 cycles (Cycle length = 7 days of treatment and 7 days of rest for a total of 14 days), which corresponds to 28 days on treatment. The percent change from baseline in platelet count was measured. Baseline was the platelet count at screening or the last available observation prior to the first dose of study drug. An analysis of treatment effect between the doses was determined using a Kruskal-Wallis test. This analysis was done to support the evaluation of plasma concentrations (Cmax and Cmin) and exposure (AUC) on haematopoiesis. Per protocol, the analysis was pre-specified to be done on participants that received bomedemstat alone. The maximum percent change from baseline in platelet count is presented.

    Time frame: Baseline (prior to first dose of study drug) and up to 28 days

  4. Maximum Percent Change From Baseline Up to 28 Days of Treatment in Reticulocyte Count in Whole Blood After Administration of Bomedemstat

    Whole blood samples were collected at time intervals during the first 4 cycles (Cycle length = 7 days of treatment and 7 days of rest for a total of 14 days), which corresponds to 28 days on treatment. The percent change from baseline in reticulocyte count was measured. Baseline was the reticulocyte count at screening or the last available observation prior to the first dose of study drug. An analysis of treatment effect between the doses was determined using a Kruskal-Wallis test. This analysis was done to support the evaluation of plasma concentrations (Cmax and Cmin) and exposure (AUC) on haematopoiesis. Per protocol, the analysis was pre-specified to be done on participants that received bomedemstat alone. The maximum percent change from baseline in reticulocyte count is presented.

    Time frame: Baseline (prior to first dose of study drug) and up to 28 days

  5. Maximum Percent Change From Baseline Up to 28 Days of Treatment in The Number of Blasts in Whole Blood After Administration of Bomedemstat

    Whole blood samples were collected at time intervals during the first 4 cycles (Cycle length = 7 days of treatment and 7 days of rest for a total of 14 days), which corresponds to 28 days on treatment. The percent change from baseline in the number of blasts was measured. Baseline was the number of blasts at screening or the last available observation prior to the first dose of study drug. An analysis of treatment effect between the doses was determined using a Kruskal-Wallis test. This analysis was done to support the evaluation of plasma concentrations (Cmax and Cmin) and exposure (AUC) on haematopoiesis. Per protocol, the analysis was pre-specified to be done on participants that received bomedemstat alone. The maximum percent change from baseline in the number of blasts is presented.

    Time frame: Baseline (prior to first dose of study drug) and up to 28 days

  6. Maximum Percent Change From Baseline Up to 28 Days of Treatment in Hemoglobin Level in Whole Blood After Administration of Bomedemstat

    Whole blood samples were collected at time intervals during the first 4 cycles (Cycle length = 7 days of treatment and 7 days of rest for a total of 14 days), which corresponds to 28 days on treatment. The percent change from baseline in the hemoglobin level was measured. Baseline was the hemoglobin level at screening or the last available observation prior to the first dose of study drug. An analysis of treatment effect between the doses was determined using a Kruskal-Wallis test. This analysis was done to support the evaluation of plasma concentrations (Cmax and Cmin) and exposure (AUC) on haematopoiesis. Per protocol, the analysis was pre-specified to be done on participants that received bomedemstat alone. The maximum percent change from baseline in hemoglobin level is presented.

    Time frame: Baseline (prior to first dose of study drug) and up to 28 days

07

Results

Posted Jul 11, 2023

Participant flow

Participant flow — Overall Study
MilestoneCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day
Started36465948
Treated36465948
Completed00000102
Not completed36465846
Withdrew: Adverse event01010100
Withdrew: Death10232104
Withdrew: Physician decision13001421
Withdrew: Protocol defined disease progression00000100
Withdrew: Participant withdrawal of consent12222121

Outcome measures

PrimaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE was defined as any undesirable physical, psychological, or behavioral effect experienced by a participant during participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not related to the study drug. This included any untoward signs or symptoms experienced by the participant from the time of first dose until completion of the study. The number of participants who experienced an AE is presented.

Time frame:
Up to approximately 24 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day
Number of Participants Who Experienced an Adverse Event (AE)36465948
PrimaryNumber of Participants Who Experienced a Serious Adverse Event (SAE)

An SAE was defined as any adverse event, whether or not related to the study drug, that resulted in any of the following outcomes: * Death * Life-threatening experience * Required or prolonged inpatient hospitalization * Persistent or significant disability/incapacity * Congenital anomaly * Important medical events that, based upon appropriate medical judgment, may have jeopardized the participant and may have required medical or surgical intervention to prevent one of the outcomes listed above. The number of participants who experienced an SAE is presented.

Time frame:
Up to approximately 24 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Serious Adverse Event (SAE)
ParticipantsCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day
Number of Participants Who Experienced a Serious Adverse Event (SAE)36455948
PrimaryNumber of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)

An AE was defined as any undesirable physical, psychological, or behavioral effect experienced by a participant during participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not related to the study drug. This included any untoward signs or symptoms experienced by the participant from the time of first dose until completion of the study. The number of participants who discontinued study treatment due to an AE is presented.

Time frame:
Up to approximately 18 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
ParticipantsCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)22330100
PrimaryNumber of Participants Who Experienced a Dose-Limiting Toxicity (DLT)

DLTs were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. A DLT was defined as any of the following events that occurs during the DLT evaluation period and is considered by the Investigator possibly, probably, or definitely related to bomedemstat: * A clinically significant bleeding event * Any Grade 4 or 5 non-haematologic adverse event * Any Grade 3 non-haematologic adverse event with failure to recover to Grade 1 within 7 days of drug cessation, with the following exceptions: ≥ Grade 3 nausea, vomiting or diarrhoea that responds to standard medical care and ≥ Grade 3 aesthenia lasting less than 14 days * Any Grade 3 electrolyte abnormality unrelated to the underlying malignancy and persisting greater than 24 hours. Per protocol, DLTs were measured during the first 28-day treatment period. The number of participants who experienced a DLT is presented.

Time frame:
Up to approximately 28 Days
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT)
ParticipantsCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day
Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT)00000000
PrimaryNumber of Participants Experiencing Any Grade 3 to 5 Adverse Events (AE) as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03

AEs were graded for severity on a scale of 1 to 5 using CTCAE criteria. Grade 1=mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2=moderate, minimal, local, or noninvasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3=severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care. Grade 4=life-threatening consequences with urgent intervention indicated. Grade 5 =death related to AE. The number of participants who experienced any Grade 3 to 5 AE is reported.

Time frame:
Up to approximately 24 months
Reported as:
Count of participants · Participants
Number of Participants Experiencing Any Grade 3 to 5 Adverse Events (AE) as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03
ParticipantsCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day
Number of Participants Experiencing Any Grade 3 to 5 Adverse Events (AE) as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0336455948
PrimaryNumber of Participants Who Experienced a Medical Event of Interest (MEOI)

Medical Events of Interest (MEOI) were adverse events that did not meet any criteria for a serious adverse event but were of particular interest in the context of the study. MEOIs included bleeding due to low platelets; electrocardiogram (ECG) QT corrected interval prolonged 481-500 milliseconds; and infection where, at a minimum, oral antibiotic, antifungal, or antiviral intervention is indicated. The number of participants with MEOIs is presented.

Time frame:
Up to approximately 24 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Medical Event of Interest (MEOI)
ParticipantsCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day
Number of Participants Who Experienced a Medical Event of Interest (MEOI)11120300
PrimaryMaximum Concentration (Cmax) of Bomedemstat Alone or Administered With Tretinoin

Cmax was defined as the maximum concentration of bomedemstat observed after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the CMax of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). Unbound plasma concentrations of bomedemstat were estimated by assuming that protein binding was 60.57%. For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the Cmax was determined for participants in Cohort 1. The LOQ of the assay was 1 ng/mL. The Cmax of bomedemstat in unbound plasma is presented.

Time frame:
Cycle 1 Day 1: predose and 1, 2, 3, and 24 hours postdose; Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
Reported as:
Mean · nanograms/milliliter
Maximum Concentration (Cmax) of Bomedemstat Alone or Administered With Tretinoin
nanograms/milliliterCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day
Cycle 1 Day 110.7 ± 12.619.6 ± 19.065.7 ± 22.9145 ± 85.566.8 ± 27.3205 ± 112
Cycle 1 Day 79.67 ± 12.018.1 ± 10.472.2 ± 26.0202 ± 111119 ± 72.1291 ± 211
PrimaryTime to Maximum Concentration (Tmax) of Bomedemstat Alone or Administered With Tretinoin

Tmax was the time required to reach the maximum concentration of bomedemstat observed after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the TMax of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the Tmax was determined for participants in Cohort 1. The Tmax of bomedemstat in plasma is presented.

Time frame:
Cycle 1 Day 1: predose and 1, 2, 3, and 24 hours postdose; Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
Reported as:
Median · hours
Time to Maximum Concentration (Tmax) of Bomedemstat Alone or Administered With Tretinoin
hoursCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day
Cycle 1 Day 11.00 (0.93 to 3.00)2.00 (0.93 to 3.05)1.00 (0.92 to 2.08)2.06 (1.00 to 3.03)1.00 (0.92 to 1.17)1.02 (0.97 to 2.50)
Cycle 1 Day 70.77 (0.53 to 1.00)1.50 (0.45 to 3.08)1.73 (0.47 to 3.05)1.53 (0.53 to 3.08)0.50 (0.50 to 0.83)0.88 (0.00 to 3.93)
PrimaryArea Under the Concentration Time Curve From Time 0 to 24 Hours (AUC0-24hr) Postdose of Bomedemstat Alone or Administered With Tretinoin

AUC0-24hr was defined as the total exposure of bomedemstat over 24 hours after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the AUC 0-24hr of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). Unbound plasma concentrations of bomedemstat were estimated by assuming that protein binding was 60.57%. For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the AUC 0-24hr was determined for participants in Cohort 1. The AUC 0-24hr of bomedemstat in unbound plasma is presented.

Time frame:
Cycle 1 Day 1: predose and 1, 2, 3, and 24 hours postdose; Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
Reported as:
Mean · hours●nanograms/milliliter
Area Under the Concentration Time Curve From Time 0 to 24 Hours (AUC0-24hr) Postdose of Bomedemstat Alone or Administered With Tretinoin
hours●nanograms/milliliterCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day
Cycle 1 Day 126.4 ± 39.278.6 ± 36.8323 ± 1421361 ± 789287 ± 1131138 ± 621
Cycle 1 Day 768.8 ± 90.4129 ± 78.0550 ± 2471361 ± 747383 ± 1161702 ± 1326
PrimaryElimination Half Life (t1/2) of Bomedemstat Alone or Administered With Tretinoin

t1/2 was the time required to divide the bomedemstat concentration by two after reaching pseudo-equilibrium after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the t1/2 of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the t1/2 was determined for participants in Cohort 1. The t1/2 of bomedemstat in plasma is presented.

Time frame:
Cycle 1 Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
Reported as:
Mean · hours
Elimination Half Life (t1/2) of Bomedemstat Alone or Administered With Tretinoin
hoursCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day
Elimination Half Life (t1/2) of Bomedemstat Alone or Administered With Tretinoin130 ± NA103 ± 23.3103 ± 8.21110 ± 49.6—59.8 ± 29.4
PrimaryApparent Total Body Clearance (CL/F) of Bomedemstat Alone or Administered With Tretinoin

CL/F was the volume of plasma from which bomedemstat was eliminated per unit of time after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the CL/F of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the CL/F was determined for participants in Cohort 1. The CL/F of bomedemstat in plasma is presented.

Time frame:
Cycle 1 Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
Reported as:
Mean · liters/hour
Apparent Total Body Clearance (CL/F) of Bomedemstat Alone or Administered With Tretinoin
liters/hourCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day
Apparent Total Body Clearance (CL/F) of Bomedemstat Alone or Administered With Tretinoin5.754 ± 7.7111.351 ± 1.246492 ± 322401 ± 211472 ± 88.3287 ± 131
PrimaryVolume of Distribution (Vz/F) of Bomedemstat Alone or Administered With Tretinoin

Vz/F was the volume of distribution of bomedemstat during the terminal phase after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the Vz/F of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the Vz/F was determined for participants in Cohort 1. The Vz/F of bomedemstat in plasma is presented.

Time frame:
Cycle 1 Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
Reported as:
Mean · liters
Volume of Distribution (Vz/F) of Bomedemstat Alone or Administered With Tretinoin
litersCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day
Volume of Distribution (Vz/F) of Bomedemstat Alone or Administered With Tretinoin56354 ± NA224527 ± 12245699822 ± 7416763895 ± 24473—22539 ± 6061
PrimaryTerminal Elimination Rate Constant (Kel) of Bomedemstat Alone or Administered With Tretinoin

kel was the rate at which bomedemstat was removed from the body by excretion or metabolism after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the kel of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). kel was obtained from the slope of the line, fitted by linear least squares regression, through the terminal points of the log (base e) concentration-time profiles. For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the kel was determined for participants in Cohort 1. The kel of bomedemstat in plasma is presented.

Time frame:
Cycle 1 Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
Reported as:
Mean · 1/hour
Terminal Elimination Rate Constant (Kel) of Bomedemstat Alone or Administered With Tretinoin
1/hourCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day
Terminal Elimination Rate Constant (Kel) of Bomedemstat Alone or Administered With Tretinoin0.0053 ± NA0.0071 ± 0.00200.0068 ± 0.00050.0074 ± 0.0031—0.0135 ± 0.0059
PrimaryEvent-free Survival (EFS) For High-risk Acute Myeloid Leukemia (AML) Participants

EFS was defined as the time from the first dose of study treatment to the date of a documented EFS event of resistance, relapse, progression, or death due to any cause as assessed by the investigator. Participants without documented events were censored at the date of the last disease assessment. The EFS, calculated using the Kaplan-Meier method, is presented.

Time frame:
Up to approximately 24 months
Reported as:
Median · Months
Event-free Survival (EFS) For High-risk Acute Myeloid Leukemia (AML) Participants
MonthsCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day
Event-free Survival (EFS) For High-risk Acute Myeloid Leukemia (AML) Participants0.87 (0.80 to 0.93)0.97 (0.93 to NA)0.93 (0.90 to 18.81)2.46 (0.97 to NA)0.93 (0.93 to 3.96)NA (0.50 to NA)1.43 (1.40 to 1.46)0.93 (0.47 to 5.59)
PrimaryEvent-free Survival (EFS) For High-risk Myelodysplastic Syndromes (MDS) Participants

EFS was defined as the time from the first dose of study treatment to the date of a documented EFS event of resistance, relapse, progression, or death due to any cause as assessed by the investigator. Participants without documented events were censored at the date of the last disease assessment. The EFS, calculated using the Kaplan-Meier method, is presented.

Time frame:
Up to approximately 24 months
Reported as:
Median · Months
Event-free Survival (EFS) For High-risk Myelodysplastic Syndromes (MDS) Participants
MonthsCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day
Event-free Survival (EFS) For High-risk Myelodysplastic Syndromes (MDS) ParticipantsNA (NA to NA)———0.75 (0.57 to 0.93)NA (NA to NA)—NA (NA to NA)
PrimaryOverall Survival (OS) For High-risk Acute Myeloid Leukemia (AML) Participants

OS was defined as the time from the first dose of study treatment until death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. The OS, calculated using the Kaplan-Meier method, is presented.

Time frame:
Up to approximately 24 months
Reported as:
Median · Months
Overall Survival (OS) For High-risk Acute Myeloid Leukemia (AML) Participants
MonthsCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day
Overall Survival (OS) For High-risk Acute Myeloid Leukemia (AML) ParticipantsNA (0.80 to NA)NA (NA to NA)18.81 (1.17 to 18.81)3.86 (1.07 to NA)NA (1.86 to NA)NA (1.36 to NA)NA (NA to NA)NA (0.47 to NA)
PrimaryOverall Survival (OS) For High-risk Myelodysplastic Syndromes (MDS) Participants

OS was defined as the time from the first dose of study treatment until death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. The OS, calculated using the Kaplan-Meier method, is presented.

Time frame:
Up to approximately 24 months
Reported as:
Median · Months
Overall Survival (OS) For High-risk Myelodysplastic Syndromes (MDS) Participants
MonthsCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day
Overall Survival (OS) For High-risk Myelodysplastic Syndromes (MDS) ParticipantsNA (NA to NA)———NA (0.57 to NA)NA (NA to NA)—NA (NA to NA)
PrimaryObjective Response Rate (ORR) For High-risk Acute Myeloid Leukemia (AML) Participants Determined Using the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2003) and Assessed by the Investigator

ORR was the percentage of participants with a response of complete remission (CR), CR with incomplete recovery (Cri), morphologic leukaemia-free state (MLFS), partial remission (PR), cytogenetic CR (CRc), molecular CR (CRm), or stable disease (SD): * CR: \<5% bone marrow (BM) blasts or blasts with Auer rods; no extramedullary disease (EMD); absolute neutrophil count ≥1000/μL; platelets ≥100,000/μL; independent of transfusion * Cri: CR with residual neutropenia (\<1,000/μL) or thrombocytopenia (\<100,000/μL); no EMD; does not require transfusion independence (TI) * MLFS: \<5% blasts in BM with marrow spicules; no EMD; does not require TI * PR: ≥ 50% decrease in BM blasts to a range of 5%-25%; Neutrophils ≥ 1,000/μL; Platelets ≥ 100,000/μL; independent of transfusion. ≤ 5% blasts is PR if Auer rods present * CRc: CR+reversion to a normal karyotype if initially abnormal * CRm: CR+no evidence of residual disease by molecular testing * SD: No evidence of CR, PR, progression, new dysplastic changes

Time frame:
Up to approximately 24 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) For High-risk Acute Myeloid Leukemia (AML) Participants Determined Using the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2003) and Assessed by the Investigator
Percentage of participantsCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day
Objective Response Rate (ORR) For High-risk Acute Myeloid Leukemia (AML) Participants Determined Using the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2003) and Assessed by the Investigator50.0 (1.3 to 98.7)16.7 (0.4 to 64.1)25.0 (0.6 to 80.6)50.0 (11.8 to 88.2)33.3 (0.8 to 90.6)28.6 (3.7 to 71.0)0.0 (NA to NA)28.6 (3.7 to 71.0)
PrimaryBest Overall Response (BOR) For High-risk Acute Myeloid Leukemia (AML) Participants Determined Using the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2003) and Assessed by the Investigator

BOR was the percentage of participants with a best overall response of CR, Cri, MLFS, PR, CRc, CRm, or SD: * CR: \<5% bone marrow (BM) blasts or blasts with Auer rods; no extramedullary disease (EMD); absolute neutrophil count ≥1000/μL; platelets ≥100,000/μL; independent of transfusion * Cri: CR with residual neutropenia (\<1,000/μL) or thrombocytopenia (\<100,000/μL); no EMD; does not require transfusion independence (TI) * MLFS: \<5% blasts in BM with marrow spicules; no EMD; does not require TI * PR: ≥ 50% decrease in BM blasts to a range of 5%-25%; Neutrophils ≥ 1,000/μL; Platelets ≥ 100,000/μL; independent of transfusion. ≤ 5% blasts is PR if Auer rods present * CRc: CR+reversion to a normal karyotype if initially abnormal * CRm: CR+no evidence of residual disease by molecular testing * SD: No evidence of CR, PR, progression, new dysplastic changes

Time frame:
Up to approximately 24 months
Reported as:
Number · Percentage of participants
Best Overall Response (BOR) For High-risk Acute Myeloid Leukemia (AML) Participants Determined Using the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2003) and Assessed by the Investigator
Percentage of participantsCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day
Complete remission (CR)0.00.00.00.00.00.00.00.0
CR with incomplete recovery (CRi)0.00.00.00.00.00.00.00.0
Morphologic leukaemia-free state (MLFS)0.00.00.00.00.00.00.00.0
Partial remission (PR)0.00.00.00.00.014.30.00.0
Cytogenetic CR (CRc)0.00.00.00.00.00.00.00.0
Molecular CR (CRm)0.00.00.00.00.00.00.00.0
Stable disease (SD)50.016.725.050.033.314.30.028.6
PrimaryObjective Response Rate (ORR) For High-risk Myelodysplastic Syndromes (MDS) Participants Determined Using the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2006) and Assessed by the Investigator

ORR was the percentage of participants with a response of complete remission (CR), partial remission (PR), marrow CR (CRm), cytogenetic response (CyR), or stable disease (SD) lasting for ≥4 weeks: * CR: ≤5% myeloblasts in the bone marrow (BM) with normal maturation of all cell lines; persistent dysplasia will be noted; Hgb ≥11 g/dL, Platelets ≥100 X 10\^9/L, Neutrophils ≥1.0 X 10\^9/L, and 0% Blasts in the peripheral blood * PR: All CR criteria if abnormal before treatment except: BM blasts decreased by ≥50% over pretreatment but still \>5%. Cellularity and morphology not relevant * CRm: ≤ 5% myeloblasts in BM and decrease by ≥50% over pretreatment. Hematological improvement responses in the peripheral blood will be noted in addition to bone marrow CR. * CyR: Complete=Disappearance of the chromosomal abnormality without appearance of new ones. Partial= ≥50% reduction of the chromosomal abnormality * SD: Failure to achieve at least PR, but no evidence of progression for \>8 weeks

Time frame:
Up to approximately 24 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) For High-risk Myelodysplastic Syndromes (MDS) Participants Determined Using the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2006) and Assessed by the Investigator
Percentage of participantsCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day
Objective Response Rate (ORR) For High-risk Myelodysplastic Syndromes (MDS) Participants Determined Using the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2006) and Assessed by the Investigator100.0 (2.5 to 100.0)———0.0 (NA to NA)0.0 (NA to NA)—0.0 (NA to NA)
PrimaryBest Overall Response (BOR) Assessed by the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2006): High-risk Myelodysplastic Syndromes (MDS) Participants

BOR was the percentage of participants with a best overall response of CR, PR, CRm, CyR, or SD lasting for ≥4 weeks: * CR: ≤5% myeloblasts in the bone marrow (BM) with normal maturation of all cell lines; persistent dysplasia will be noted; Hgb ≥11 g/dL, Platelets ≥100 X 10\^9/L, Neutrophils ≥1.0 X 10\^9/L, and 0% Blasts in the peripheral blood * PR: All CR criteria if abnormal before treatment except: BM blasts decreased by ≥50% over pretreatment but still \>5%. Cellularity and morphology not relevant * CRm: ≤ 5% myeloblasts in BM and decrease by ≥50% over pretreatment. Hematological improvement responses in the peripheral blood will be noted in addition to bone marrow CR. * CyR: Complete=Disappearance of the chromosomal abnormality without appearance of new ones. Partial= ≥50% reduction of the chromosomal abnormality * SD: Failure to achieve at least PR, but no evidence of progression for \>8 weeks

Time frame:
Up to approximately 24 months
Reported as:
Number · Percentage of participants
Best Overall Response (BOR) Assessed by the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2006): High-risk Myelodysplastic Syndromes (MDS) Participants
Percentage of participantsCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day
Complete remission (CR)0.0———0.00.0—0.0
Partial remission (PR)0.0———0.00.0—0.0
Marrow CR (CRm)0.0———0.00.0—0.0
Cytogenetic response (CyR)0.0———0.00.0—0.0
Stable disease (SD)100.0———0.00.0—0.0
SecondaryMaximum Percent Change From Baseline Up to 28 Days of Treatment in Erythrocyte Count in Whole Blood After Administration of Bomedemstat

Whole blood samples were collected at time intervals during the first 4 cycles (Cycle length = 7 days of treatment and 7 days of rest for a total of 14 days), which corresponds to 28 days on treatment. The percent change from baseline in erythrocyte count was measured. Baseline was the erythrocyte count at screening or the last available observation prior to the first dose of study drug. An analysis of treatment effect between the doses was determined using a Kruskal-Wallis test. This analysis was done to support the evaluation of plasma concentrations (Cmax and Cmin) and exposure (AUC) on haematopoiesis. Per protocol, the analysis was pre-specified to be done on participants that received bomedemstat alone. The maximum percent change from baseline in erythrocyte count is presented.

Time frame:
Baseline (prior to first dose of study drug) and up to 28 days
Reported as:
Mean · Percent change
Maximum Percent Change From Baseline Up to 28 Days of Treatment in Erythrocyte Count in Whole Blood After Administration of Bomedemstat
Percent changeCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/Day
Maximum Percent Change From Baseline Up to 28 Days of Treatment in Erythrocyte Count in Whole Blood After Administration of Bomedemstat4.4 ± 6.6616.7 ± 19.4317.0 ± 5.8321.4 ± 14.97
Statistical analysis
  • Cohort 1a: Bomedemstat 0.75 mg/kg/Day vs Cohort 1b: Bomedemstat 1.5 mg/kg/Day vs Cohort 1c: Bomedemstat 3 mg/kg/Day vs Cohort 1d: Bomedemstat 6 mg/kg/Day · Kruskal-Wallis · p = 0.3868p-value of the treatment effect was calculated between all dose arms with ≥3 participants
SecondaryMaximum Percent Change From Baseline Up to 28 Days of Treatment in Neutrophil Count in Whole Blood After Administration of Bomedemstat

Whole blood samples were collected at time intervals during the first 4 cycles (Cycle length = 7 days of treatment and 7 days of rest for a total of 14 days), which corresponds to 28 days on treatment. The percent change from baseline in neutrophil count was measured. Baseline was the neutrophil count at screening or the last available observation prior to the first dose of study drug. An analysis of treatment effect between the doses was determined using a Kruskal-Wallis test. This analysis was done to support the evaluation of plasma concentrations (Cmax and Cmin) and exposure (AUC) on haematopoiesis. Per protocol, the analysis was pre-specified to be done on participants that received bomedemstat alone. The maximum percent change from baseline in neutrophil count is presented.

Time frame:
Baseline (prior to first dose of study drug) and up to 28 days
Reported as:
Mean · Percent change
Maximum Percent Change From Baseline Up to 28 Days of Treatment in Neutrophil Count in Whole Blood After Administration of Bomedemstat
Percent changeCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/Day
Maximum Percent Change From Baseline Up to 28 Days of Treatment in Neutrophil Count in Whole Blood After Administration of Bomedemstat198.4 ± 206.33223.3 ± 259.61198.8 ± 273.543218.0 ± 7780.65
Statistical analysis
  • Cohort 1a: Bomedemstat 0.75 mg/kg/Day vs Cohort 1b: Bomedemstat 1.5 mg/kg/Day vs Cohort 1c: Bomedemstat 3 mg/kg/Day vs Cohort 1d: Bomedemstat 6 mg/kg/Day · Kruskal-Wallis · p = 0.7744p-value of the treatment effect was calculated between all dose arms with ≥3 participants
SecondaryMaximum Percent Change From Baseline Up to 28 Days of Treatment in Platelet Count in Whole Blood After Administration of Bomedemstat

Whole blood samples were collected at time intervals during the first 4 cycles (Cycle length = 7 days of treatment and 7 days of rest for a total of 14 days), which corresponds to 28 days on treatment. The percent change from baseline in platelet count was measured. Baseline was the platelet count at screening or the last available observation prior to the first dose of study drug. An analysis of treatment effect between the doses was determined using a Kruskal-Wallis test. This analysis was done to support the evaluation of plasma concentrations (Cmax and Cmin) and exposure (AUC) on haematopoiesis. Per protocol, the analysis was pre-specified to be done on participants that received bomedemstat alone. The maximum percent change from baseline in platelet count is presented.

Time frame:
Baseline (prior to first dose of study drug) and up to 28 days
Reported as:
Mean · Percent change
Maximum Percent Change From Baseline Up to 28 Days of Treatment in Platelet Count in Whole Blood After Administration of Bomedemstat
Percent changeCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/Day
Maximum Percent Change From Baseline Up to 28 Days of Treatment in Platelet Count in Whole Blood After Administration of Bomedemstat21.9 ± 18.1530.4 ± 73.39313.6 ± 529.948.1 ± 20.79
Statistical analysis
  • Cohort 1a: Bomedemstat 0.75 mg/kg/Day vs Cohort 1b: Bomedemstat 1.5 mg/kg/Day vs Cohort 1c: Bomedemstat 3 mg/kg/Day vs Cohort 1d: Bomedemstat 6 mg/kg/Day · Kruskal-Wallis · p = 0.5080p-value of the treatment effect was calculated between all dose arms with ≥3 participants
SecondaryMaximum Percent Change From Baseline Up to 28 Days of Treatment in Reticulocyte Count in Whole Blood After Administration of Bomedemstat

Whole blood samples were collected at time intervals during the first 4 cycles (Cycle length = 7 days of treatment and 7 days of rest for a total of 14 days), which corresponds to 28 days on treatment. The percent change from baseline in reticulocyte count was measured. Baseline was the reticulocyte count at screening or the last available observation prior to the first dose of study drug. An analysis of treatment effect between the doses was determined using a Kruskal-Wallis test. This analysis was done to support the evaluation of plasma concentrations (Cmax and Cmin) and exposure (AUC) on haematopoiesis. Per protocol, the analysis was pre-specified to be done on participants that received bomedemstat alone. The maximum percent change from baseline in reticulocyte count is presented.

Time frame:
Baseline (prior to first dose of study drug) and up to 28 days
Reported as:
Mean · Percent change
Maximum Percent Change From Baseline Up to 28 Days of Treatment in Reticulocyte Count in Whole Blood After Administration of Bomedemstat
Percent changeCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/Day
Maximum Percent Change From Baseline Up to 28 Days of Treatment in Reticulocyte Count in Whole Blood After Administration of Bomedemstat47.3 ± 102.5157.1 ± 52.48133.5 ± 158.0326.6 ± 51.64
Statistical analysis
  • Cohort 1a: Bomedemstat 0.75 mg/kg/Day vs Cohort 1b: Bomedemstat 1.5 mg/kg/Day vs Cohort 1c: Bomedemstat 3 mg/kg/Day vs Cohort 1d: Bomedemstat 6 mg/kg/Day · Kruskal-Wallis · p = 0.6109p-value of the treatment effect was calculated between all dose arms with ≥3 participants
SecondaryMaximum Percent Change From Baseline Up to 28 Days of Treatment in The Number of Blasts in Whole Blood After Administration of Bomedemstat

Whole blood samples were collected at time intervals during the first 4 cycles (Cycle length = 7 days of treatment and 7 days of rest for a total of 14 days), which corresponds to 28 days on treatment. The percent change from baseline in the number of blasts was measured. Baseline was the number of blasts at screening or the last available observation prior to the first dose of study drug. An analysis of treatment effect between the doses was determined using a Kruskal-Wallis test. This analysis was done to support the evaluation of plasma concentrations (Cmax and Cmin) and exposure (AUC) on haematopoiesis. Per protocol, the analysis was pre-specified to be done on participants that received bomedemstat alone. The maximum percent change from baseline in the number of blasts is presented.

Time frame:
Baseline (prior to first dose of study drug) and up to 28 days
Reported as:
Mean · Percent change
Maximum Percent Change From Baseline Up to 28 Days of Treatment in The Number of Blasts in Whole Blood After Administration of Bomedemstat
Percent changeCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/Day
Maximum Percent Change From Baseline Up to 28 Days of Treatment in The Number of Blasts in Whole Blood After Administration of Bomedemstat368.0 ± 399.542478.3 ± 3278.969.7 ± 25.232841.4 ± 6046.61
Statistical analysis
  • Cohort 1a: Bomedemstat 0.75 mg/kg/Day vs Cohort 1b: Bomedemstat 1.5 mg/kg/Day vs Cohort 1c: Bomedemstat 3 mg/kg/Day vs Cohort 1d: Bomedemstat 6 mg/kg/Day · Kruskal-Wallis · p = 0.1151p-value of the treatment effect was calculated between all dose arms with ≥3 participants
SecondaryMaximum Percent Change From Baseline Up to 28 Days of Treatment in Hemoglobin Level in Whole Blood After Administration of Bomedemstat

Whole blood samples were collected at time intervals during the first 4 cycles (Cycle length = 7 days of treatment and 7 days of rest for a total of 14 days), which corresponds to 28 days on treatment. The percent change from baseline in the hemoglobin level was measured. Baseline was the hemoglobin level at screening or the last available observation prior to the first dose of study drug. An analysis of treatment effect between the doses was determined using a Kruskal-Wallis test. This analysis was done to support the evaluation of plasma concentrations (Cmax and Cmin) and exposure (AUC) on haematopoiesis. Per protocol, the analysis was pre-specified to be done on participants that received bomedemstat alone. The maximum percent change from baseline in hemoglobin level is presented.

Time frame:
Baseline (prior to first dose of study drug) and up to 28 days
Reported as:
Mean · Percent change
Maximum Percent Change From Baseline Up to 28 Days of Treatment in Hemoglobin Level in Whole Blood After Administration of Bomedemstat
Percent changeCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/Day
Maximum Percent Change From Baseline Up to 28 Days of Treatment in Hemoglobin Level in Whole Blood After Administration of Bomedemstat1262.1 ± 429.99476.5 ± 710.2812.6 ± 3.76134.4 ± 296.96
Statistical analysis
  • Cohort 1a: Bomedemstat 0.75 mg/kg/Day vs Cohort 1b: Bomedemstat 1.5 mg/kg/Day vs Cohort 1c: Bomedemstat 3 mg/kg/Day vs Cohort 1d: Bomedemstat 6 mg/kg/Day · Kruskal-Wallis · p = 0.0791p-value of the treatment effect was calculated between all dose arms with ≥3 participants

Adverse events

Collected over Up to approximately 24 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1a: Bomedemstat 0.75 mg/kg/Day1/3 (33.3%)3/3 (100%)3/3 (100%)
Cohort 1b: Bomedemstat 1.5 mg/kg/Day0/6 (0%)6/6 (100%)6/6 (100%)
Cohort 1c: Bomedemstat 3 mg/kg/Day2/4 (50%)4/4 (100%)4/4 (100%)
Cohort 1d: Bomedemstat 6 mg/kg/Day3/6 (50%)5/6 (83.3%)6/6 (100%)
Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day2/5 (40%)5/5 (100%)5/5 (100%)
Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day2/9 (22.2%)9/9 (100%)9/9 (100%)
Cohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day1/4 (25%)4/4 (100%)4/4 (100%)
Cohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day4/8 (50%)8/8 (100%)8/8 (100%)
Most frequent serious events
Showing 10 of 66
Most frequent serious events
EventCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day
Febrile neutropeniaBlood and lymphatic system disorders0/33/62/44/61/54/90/44/8
SepsisInfections and infestations0/30/62/40/61/50/90/40/8
CellulitisInfections and infestations0/32/60/40/62/51/91/40/8
Ear painEar and labyrinth disorders1/30/60/40/60/50/90/40/8
MalaiseGeneral disorders1/30/60/40/60/50/90/40/8
PyrexiaGeneral disorders1/31/60/40/60/50/90/41/8
EpiglottitisInfections and infestations1/30/60/40/60/50/90/40/8
InfectionInfections and infestations1/30/60/40/60/50/90/40/8
Periorbital infectionInfections and infestations1/30/60/40/60/50/90/40/8
Subdural haemorrhageInjury, poisoning and procedural complications1/30/60/40/60/50/90/40/8
Most frequent other events
Showing 10 of 309
Most frequent other events
EventCohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day
ThrombocytopeniaBlood and lymphatic system disorders3/34/61/43/62/53/91/43/8
DiarrhoeaGastrointestinal disorders2/34/64/42/61/56/94/47/8
NauseaGastrointestinal disorders3/33/62/45/62/57/92/45/8
HypomagnesaemiaMetabolism and nutrition disorders0/33/64/41/61/56/91/41/8
Decreased appetiteMetabolism and nutrition disorders1/31/63/40/61/53/91/43/8
VomitingGastrointestinal disorders0/32/62/44/62/54/91/45/8
Oedema peripheralGeneral disorders1/34/62/40/61/54/90/45/8
HypokalaemiaMetabolism and nutrition disorders1/33/62/43/62/56/92/43/8
HypophosphataemiaMetabolism and nutrition disorders0/31/61/41/60/56/92/42/8
DizzinessNervous system disorders2/32/61/41/60/51/90/40/8

Baseline characteristics

All participants who received ≥1 dose of study treatment

Age, Continuous
Age, Continuous(Years)Cohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayTotal
Mean72.3 ± 10.0274.2 ± 9.2474.0 ± 10.9566.8 ± 11.1467.2 ± 14.6571.8 ± 9.0068.5 ± 2.0870.5 ± 11.6570.6 ± 9.98
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayTotal
Female1111462319
Male2535132526
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayTotal
Hispanic or Latino010000001
Not Hispanic or Latino2446483637
Unknown or Not Reported110011127
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayTotal
American Indian or Alaska Native000000000
Asian000100001
Native Hawaiian or Other Pacific Islander000000000
Black or African American000000000
White2545574739
More than one race000000000
Unknown or Not Reported110002015
Disease Diagnosis
Disease Diagnosis(Participants)Cohort 1a: Bomedemstat 0.75 mg/kg/DayCohort 1b: Bomedemstat 1.5 mg/kg/DayCohort 1c: Bomedemstat 3 mg/kg/DayCohort 1d: Bomedemstat 6 mg/kg/DayCohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/DayCohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayCohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/DayTotal
AML2646374739
MDS100022016
08

Study locations

1 site
  • Royal Adelaide Hospital
    Adelaide, South Australia, Australia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Oct 2018, 24 months.

Results were first posted in Jul 2023, 4 years 8 months after primary completion.

Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's 24 months is below that.

Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2016
First posted
Jul 25, 2016
StartActual
Oct 6, 2016
Primary completionActual
Oct 30, 2018
CompletionActual
Oct 30, 2018
Results first posted
Jul 11, 2023
Last update
Jul 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02842827
Responsible party
Sponsor
First posted
Jul 25, 2016
Start date
Oct 6, 2016
Primary completion
Oct 30, 2018
Completion
Oct 30, 2018
Results posted
Jul 11, 2023
Last update
Jul 11, 2023

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bomedemstat

Start the discussion